Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62018TA0321

Case T-321/18: Judgment of the General Court of 6 March 2019 — Serenity Pharmaceuticals v EUIPO — Gebro Holding (NOCUVANT) (EU trade mark — Opposition proceedings — Application for EU word mark NOCUVANT — Earlier word marks NOCUTIL — Proof of genuine use — Article 47(2) of Regulation (EU) 2017/1001 — Relative ground for refusal — Likelihood of confusion — Similarity of the signs — Article 8(1)(b) of Regulation 2017/1001)

OJ C 139, 15.4.2019, p. 51–52 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

15.4.2019   

EN

Official Journal of the European Union

C 139/51


Judgment of the General Court of 6 March 2019 — Serenity Pharmaceuticals v EUIPO — Gebro Holding (NOCUVANT)

(Case T-321/18) (1)

(EU trade mark - Opposition proceedings - Application for EU word mark NOCUVANT - Earlier word marks NOCUTIL - Proof of genuine use - Article 47(2) of Regulation (EU) 2017/1001 - Relative ground for refusal - Likelihood of confusion - Similarity of the signs - Article 8(1)(b) of Regulation 2017/1001)

(2019/C 139/51)

Language of the case: English

Parties

Applicant: Serenity Pharmaceuticals LLC (Milford, Pennsylvania, United States) (represented by: J. Day, Solicitor)

Defendant: European Union Intellectual Property Office (represented by: A. Lukošiūtė and H. O’Neill, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Gebro Holding GmbH (Fieberbrunn, Austria) (represented by: M. Konzett, lawyer)

Re:

Action brought against the decision of the Second Board of Appeal of EUIPO of 8 March 2018 (Case R 584/2017-2), relating to opposition proceedings between Gebro Holding and Allergan, Inc.

Operative part of the judgment

The Court:

1.

Dismisses the action;

2.

Orders Serenity Pharmaceuticals LLC to pay the costs.


(1)  OJ C 240, 9.7.2018.


Top